Molnlycke

Mölnlycke, a Swedish pharmaceutical preparation manufacturer, reported total emissions of approximately 533 million kg CO2e in 2025. This includes Scope 1 emissions of about 47.9 million kg CO2e, Scope 2 market-based emissions of roughly 1.9 million kg CO2e, and Scope 3 emissions of approximately 483.3 million kg CO2e.

Looking back, Mölnlycke's total emissions were approximately 548.8 million kg CO2e in 2024, 518 million kg CO2e in 2023, 581.5 million kg CO2e in 2022, and 648.9 million kg CO2e in 2021.

Mölnlycke Health Care AB has set ambitious climate commitments. The company aims to achieve net-zero greenhouse gas emissions across its value chain by 2050.

For near-term targets, Mölnlycke Health Care AB commits to reducing absolute Scope 1 and Scope 2 GHG emissions by 50% by 2030, using a 2021 base year. Furthermore, the company committed to increasing active annual sourcing of renewable electricity from 23% in 2021 to 100% by the end of 2024 and maintaining 100% renewable electricity sourcing through 2030. Mölnlycke also plans to reduce absolute Scope 3 GHG emissions from purchased goods and services, fuel and energy-related activities, upstream transportation and distribution, and waste generated in operations by 20% by 2028, also from a 2021 base year. They also aim for 63% of their suppliers (by emissions covering purchased goods and services, capital goods, and upstream transportation and distribution) to have science-based targets by 2028.

For long-term targets, Mölnlycke Health Care AB commits to reducing absolute Scope 1 and Scope 2 GHG emissions by 90% by 2050 from a 2021 base year. Additionally, they aim to reduce Scope 3 GHG emissions by 97% per tonne of sold product within the same timeframe. These targets are consistent with reductions required to limit global warming to 1.5°C, according to the Science Based Targets initiative (SBTi).